Literature DB >> 18668293

Prospective comparison of FDG and FET PET/CT in patients with head and neck squamous cell carcinoma.

S Balogova1, S Périé, K Kerrou, D Grahek, F Montravers, B Angelard, B Susini, P El Chater, J Lacau St Guily, J N Talbot.   

Abstract

AIM: The clinical usefulness of 2-deoxy-2-[F-18]fluoro-D-glucose-positron emission tomography (FDG-PET) in head and neck squamous cell carcinoma (HNSCC) is now well-documented. However, its sensitivity is greater than its specificity due to false-positive results in inflammatory or infectious lesions, which are frequent in this area, in particular after treatment by surgery and/or radiotherapy. O-2-fluoro-(18F)-ethyl-L-thyrosine (FET) has been reported not to be taken up by such lesions, and a preliminary study indicated that this may be clinically useful in HNSCC. We performed a prospective study to compare the diagnostic performances of FDG and FET PET/CT in the different settings of HNSCC.
MATERIALS AND METHODS: Twenty-seven patients (20 men and seven women, aged 48-76, among 30 patients included) and 69 suspected cancer sites are now evaluable on basis of postsurgical histology and/or follow-up greater than 6 months; 15 patients were referred for initial staging and 12 during posttherapy follow-up, a recurrence being suspected in eight of them. FDG and FET PET/CT were performed on two different days, the patient fasting for 6 h, 1 h after injection of 5 MBq/kg of body mass of each radiopharmaceutical. Both PET/CT examinations were blind read more than 6 months after the end of inclusions in a random order for each tracer and with a time interval greater than 1 month between FDG and FET PET/CT blind readings.
RESULTS: Overall diagnostic performances, derived from blind reading: FDG PET/CT on a per patient basis: sensitivity 100%, specificity 71%, accuracy 93%; FDG PET/CT on a per site basis: sensitivity 95%, specificity 63%, accuracy 83%; FET PET/CT on a per patient basis: sensitivity 70%, specificity 100%, accuracy 78%; FET PET/CT on a per site basis: sensitivity 64%, specificity 100%, accuracy 78%. At site level, sensitivity was significantly greater with FDG (p<0.02) and specificity with FET (p<0.01). The statistical level of significance was not reached at patient level.
CONCLUSION: Although its good specificity was confirmed, FET did not appear to be suited as a first-line PET tracer in HNSCC imaging and cannot replace FDG for staging due to insufficient sensitivity. However, it was useful in a few selected cases to favor a wait and see attitude when a FDG+ FET- focus was discovered in patients referred for systematic FDG PET during follow-up. In contrast, second primary cancers should not be ruled out if FDG was clearly positive in the lungs or the digestive tract.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18668293     DOI: 10.1007/s11307-008-0155-2

Source DB:  PubMed          Journal:  Mol Imaging Biol        ISSN: 1536-1632            Impact factor:   3.488


  9 in total

1.  Evaluation of suspected local recurrence in head and neck cancer: a comparison between PET and PET/CT for biopsy proven lesions.

Authors:  Benjamin S Halpern; Kristen Yeom; Barbara J Fueger; Robert B Lufkin; Johannes Czernin; Martin Allen-Auerbach
Journal:  Eur J Radiol       Date:  2007-01-12       Impact factor: 3.528

2.  F-18-fluoro-deoxy-glucose positron-emission tomography scanning in detection of local recurrence after radiotherapy for laryngeal/ pharyngeal cancer.

Authors:  C H Terhaard; V Bongers; P P van Rijk; G J Hordijk
Journal:  Head Neck       Date:  2001-11       Impact factor: 3.147

3.  Diagnostic and prognostic value of [(18)F]fluorodeoxyglucose positron emission tomography for recurrent head and neck squamous cell carcinoma.

Authors:  R J Wong; D T Lin; H Schöder; S G Patel; M Gonen; S Wolden; D G Pfister; J P Shah; S M Larson; D H Kraus
Journal:  J Clin Oncol       Date:  2002-10-15       Impact factor: 44.544

4.  O-(2-[18F]fluoroethyl)-L-tyrosine and L-[methyl-11C]methionine uptake in brain tumours: initial results of a comparative study.

Authors:  W A Weber; H J Wester; A L Grosu; M Herz; B Dzewas; H J Feldmann; M Molls; G Stöcklin; M Schwaiger
Journal:  Eur J Nucl Med       Date:  2000-05

5.  Detection of malignant tumors: whole-body PET with fluorine 18 alpha-methyl tyrosine versus FDG--preliminary study.

Authors:  T Inoue; K Koyama; N Oriuchi; S Alyafei; Z Yuan; H Suzuki; K Takeuchi; Y Tomaru; K Tomiyoshi; J Aoki; K Endo
Journal:  Radiology       Date:  2001-07       Impact factor: 11.105

6.  18F-FET PET compared with 18F-FDG PET and CT in patients with head and neck cancer.

Authors:  Dirk Pauleit; Andre Zimmermann; Gabriele Stoffels; Dagmar Bauer; Jörn Risse; Michael O Flüss; Kurt Hamacher; Heinz H Coenen; Karl-Josef Langen
Journal:  J Nucl Med       Date:  2006-02       Impact factor: 10.057

7.  Comparative evaluation of FET and FDG for differentiating lung carcinoma from inflammation in mice.

Authors:  Chih-Hsien Chang; Hsin-Ell Wang; Shi-Yuan Wu; Kuo-Hsien Fan; Tung-Hu Tsai; Te-Wei Lee; Shiang-Rong Chang; Ren-Shyan Liu; Chieh-Fu Chen; Chin-Hsiung Chen; Ying-Kai Fu
Journal:  Anticancer Res       Date:  2006 Mar-Apr       Impact factor: 2.480

8.  PET with O-(2-18F-Fluoroethyl)-L-Tyrosine in peripheral tumors: first clinical results.

Authors:  Dirk Pauleit; Gabriele Stoffels; Winfried Schaden; Kurt Hamacher; Dagmar Bauer; Lutz Tellmann; Hans Herzog; Stefan Bröer; Heinz H Coenen; Karl-Josef Langen
Journal:  J Nucl Med       Date:  2005-03       Impact factor: 10.057

9.  Diagnosis of maxillofacial tumor with L-3-[18f]-fluoro-alpha-methyltyrosine (FMT) PET: a comparative study with FDG-PET.

Authors:  Mitsuyuki Miyakubo; Noboru Oriuchi; Yoshito Tsushima; Tetsuya Higuchi; Keiko Koyama; Kiyokazu Arai; Bishnuhari Paudyal; Yasuhiko Iida; Hirofumi Hanaoka; Tomohiro Ishikita; Yoshiki Nakasone; Akihide Negishi; Kenji Mogi; Keigo Endo
Journal:  Ann Nucl Med       Date:  2007-02       Impact factor: 2.668

  9 in total
  8 in total

1.  Selecting the optimal image segmentation strategy in the era of multitracer multimodality imaging: a critical step for image-guided radiation therapy.

Authors:  Sandip Basu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-01-08       Impact factor: 9.236

Review 2.  PET/CT in head and neck cancer: an update.

Authors:  Roland Hustinx; Giovanni Lucignani
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-03       Impact factor: 9.236

Review 3.  PET imaging biomarkers in head and neck cancer.

Authors:  Sarah Differding; François-Xavier Hanin; Vincent Grégoire
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-01-09       Impact factor: 9.236

4.  18F-FET PET/CT in advanced head and neck squamous cell carcinoma: an intra-individual comparison with 18F-FDG PET/CT.

Authors:  Stephan Kurt Haerle; Dorothee R Fischer; Daniel T Schmid; Nader Ahmad; Gerhard F Huber; Alfred Buck
Journal:  Mol Imaging Biol       Date:  2011-10       Impact factor: 3.488

Review 5.  Alternative PET tracers in head and neck cancer. A review.

Authors:  Jan Wedman; Jan Pruim; Jan L N Roodenburg; Gyorgy B Halmos; Johannes A Langedijk; Rudi A J O Dierckx; Bernard F A M van der Laan
Journal:  Eur Arch Otorhinolaryngol       Date:  2012-12-27       Impact factor: 2.503

6.  The impact of 18 F-FET PET-CT on target definition in image-guided stereotactic radiotherapy in patients with skull base lesions.

Authors:  Harun Badakhshi; Reinhold Graf; Vikas Prasad; Volker Budach
Journal:  Cancer Imaging       Date:  2014-06-25       Impact factor: 3.909

7.  Clinical Applications of FDG PET and PET/CT in Head and Neck Cancer.

Authors:  Akram Al-Ibraheem; Andreas Buck; Bernd Joachim Krause; Klemens Scheidhauer; Markus Schwaiger
Journal:  J Oncol       Date:  2009-08-20       Impact factor: 4.375

8.  Contribution of (18)F-Fluoro-ethyl-tyrosine Positron Emission Tomography to Target Volume Delineation in Stereotactic Radiotherapy of Malignant Cranial Base Tumours: First Clinical Experience.

Authors:  Reinhold Graf; Michail Plotkin; Fonyuy Nyuyki; Peter Wust; Reinhard Wurm; Volker Budach; Winfried Brenner; Daniel Fahdt
Journal:  Int J Mol Imaging       Date:  2012-10-08
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.